UW-Green Bay educator joins Great Lakes research voyage aboard EPA vessel
Fish, who serves as the Tribal Engagement Coordinator at UW-Green Bay, works with tribal schools to create and promote educational programs focused on wetlands, estuaries, and coastlines. His work connects water science to Wisconsin First Nation history, culture, and sovereignty.
Wisconsin State Patrol to soon kick off 'Trooper in a Truck'
'I'm really looking forward to doing scientific research that can directly impact our understanding of the tribal history and presence in the Bay of Green Bay and also the Great Lakes in general,' Fish said before the trip. 'With some of the lakebed mapping efforts happening through this project, we could find Indigenous sites, which could bring what many consider ancient tribal history into a contemporary light.'
The voyage is part of a broader partnership between the EPA Great Lakes National Program Office and NOAA, with support from the Great Lakes Restoration Initiative. During the expedition, educators work alongside researchers to study Lake Michigan, gaining knowledge and tools to bring back to their classrooms.
The Lake Michigan expedition is hosted by Illinois-Indiana Sea Grant and Wisconsin Sea Grant, in partnership with the Center for Great Lakes Literacy (CGLL), which is a collaborative network of Sea Grant educators from across the Great Lakes region.
Wisconsin elections commission says former Madison clerk broke laws
The CGLL's Shipboard Science Immersions aim to promote Great Lakes science education and build lasting relationships between researchers and educators. Through hands-on experiences and fieldwork, the initiative fosters informed stewardship and environmental literacy among students, teachers, and communities throughout the Great Lakes basin.
The expedition lasts from July 7-13.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
NASA and SpaceX will launch a resupply mission to the ISS
NASA and SpaceX will launch the 33rd commercial resupply mission to the ISS from Cape Canaveral at 2:45 a.m. EDT on Sunday, August 24. The SpaceX Dragon spacecraft is scheduled to dock with the ISS on Monday, August 25, at 7:30 a.m. EDT, carrying more than 5,000 pounds of supplies and scientific experiments. Its objectives include delivering vital materials to the crew and performing experiments that could support future space missions and medical progress on Earth. Onboard science experiments include bone-forming stem cells to study bone loss prevention, materials for 3D-printed medical implants to improve nerve damage treatments, bioprinted liver tissue for blood vessel development in microgravity, and supplies for 3D printing metal cubes. The Dragon spacecraft will perform a reboost to maintain the ISS's altitude, using an independent propellant system to fuel two Draco engines with burns planned throughout Fall 2025. The Dragon spacecraft is expected to stay at the ISS until December, then return to Earth with research and cargo, landing in the Pacific Ocean off the coast of California. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live. Solve the daily Crossword
Medscape
2 days ago
- Medscape
Q&A: Bladder Cancer Treatment Challenges
Kyle A. Richards, MD Bladder cancer is a prevalent malignancy affecting the urinary system, with symptoms including gross or microscopic hematuria, urinary frequency, and pelvic pain. Medscape spoke with Kyle A. Richards, MD, an associate professor in the Department of Urology at University of Wisconsin School of Medicine and Public Health, about the current challenges in bladder cancer diagnosis and treatment. What are the challenges with managing early stage bladder cancer? Most patients are diagnosed with early stage bladder cancer, or non-muscle invasive bladder cancer (NMIBC). Once the initial cancer is removed via transurethral resection of bladder tumor (TURBT), lifelong surveillance is needed to detect recurrence, which may occur at any time in a high rate of patients. For high-risk NMIBC, monitoring using office cystoscopy is recommended every 3 months for the first 2 years after diagnosis. Noninvasive urine biomarkers aim to reduce this significant burden. One such biomarker, CxMonitor, has shown promise in early phase clinical studies, but additional trials are needed. Another challenge is the difficulty of detecting all the cancer burden in the bladder following TURBT using the typical 'white light' source. Narrow band imaging and blue light cystoscopy aim to address this. Though the data are mixed, these technologies appear to improve detection rates and possibly the completeness of TURBT. However, a randomized trial comparing blue-light-guided and standard white-light-guided TURBT showed no difference in recurrence rates. How do you determine the staging of bladder cancer? Bladder cancer staging is based on the pathology report from TURBT plus axial imaging of the chest, abdomen, and pelvis to evaluate for metastatic disease. FDG PET scan may help assess for distant metastasis, and CT urogram often helps evaluate for upper tract urothelial tumors. For localized NMIBC, we typically assess the need for adjuvant therapy following TURBT to reduce the risk for recurrence or progression. Standard-of-care treatment for high-risk NMIBC is bacillus Calmette-Guérin (BCG). Because of the BCG shortage worldwide and lack of responsiveness to BCG in some patients, additional treatments have been explored, with sequential chemotherapy — specifically gemcitabine + docetaxel (gem/doce) — gaining the most traction. We have no reliable tools to predict which patients are less likely to respond to BCG or gem/doce. Computational histologic artificial intelligence has been used to develop assays to help predict response to BCG, preserve BCG for patients most likely to respond, and route others to different treatments. More investigation is needed to see how these tests perform prospectively. How do you manage patients with bladder cancer? Surgery is often needed to remove the primary bladder tumor. Adjuvant intravesical therapies following a complete TURBT are recommended for intermediate- or high-risk patients with NMIBC to help prevent recurrence and progression. For patients with suspected low-risk NMIBC, a single dose of gemcitabine immediately after TURBT reduced the risk for recurrence from 47% to 35%. Complications following TURBT are typically minor. In a prospective study of 159 patients undergoing TURBT, 10% had an unplanned emergency room visit, 79% experienced hematuria, and one third had bladder spasms and incontinence. Patient education and preoperative counseling may help reduce the burden of complications and postoperative readmission. Can you tell us about recently approved bladder cancer therapies? Perioperative durvalumab was studied in combination with gemcitabine and cisplatin (GC) for neoadjuvant therapy in patients with muscle invasive bladder cancer. This three-drug regimen was compared to the standard GC regimen in the NIAGARA trial. Overall survival at 2 years following cystectomy was improved by 8% in the durvalumab arm. Nogapendekin alfa inbakicept was evaluated in patients with NMIBC unresponsive to BCG. This drug modulates the local immune microenvironment in the bladder as an IL-15 super-agonist and must be given with BCG. In the pivotal study, 71% of patients had an initial complete response with a median duration of 26 months. Mitomycin intravesical solution has been investigated in patients with low-grade intermediate-risk NMIBC, who often must undergo frequent TURBTs that can negatively affect quality of life. This agent, given intravesically, delivers a slow release of chemotherapy that ablates the tumors. With this strategy, 80% of patients were tumor free without requiring surgery at 3 months, and 82% remained free of cancer 12 months later. It has similar efficacy to TURBT but involves six weekly instillations vs one trip to the operating room. Can you tell us more about upcoming therapies and clinical trial results in the near future? I will be excited to see the results from the BRIDGE trial (ECOG-ACRIN EA8212), which met its patient accrual in July 2025. This trial randomized over 700 newly diagnosed patients who were BCG naive with high-grade NMIBC to BCG vs gem/doce. The primary objective is to assess event-free survival. Patient-reported outcomes are also being collected. TAR-200, which is under FDA review, involves a novel drug delivery system that is inserted in the bladder and slowly releases gemcitabine to treat early stages of bladder cancer. A July 2025 press release cited an 82% complete response rate against bladder cancer, with 52% remaining cancer free for at least 1 year.
Yahoo
2 days ago
- Yahoo
Maxwell Biosciences Marks Scientist Appreciation Day With Renewed Call to Recognize Scientists
Company holiday celebrates scientific impact and invites underrecognized researchers to connect Austin, Texas--(Newsfile Corp. - August 18, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today celebrates Scientist Appreciation Day, an official company holiday that honors the essential contributions of scientists. The observance is a call to give scientists greater visibility and broader recognition of their work at a time when scientific research faces growing challenges in visibility, funding and public support. To view an enhanced version of this graphic, please visit: Scientist Appreciation Day is celebrated annually by Maxwell's team. This year, the company is sharing its message more broadly to recognize the impact of people behind global scientific progress and to invite scientists working on complex or overlooked problems to reach out and connect. Moving forward, Maxwell's observance of Scientist Appreciation Day will take place on the third Friday in August. "At Maxwell, we believe scientists are heroes— almost like wizards working to improve the human experience while exploring the inner cosmos," said Scotch McClure, founder, CEO and chairman of Maxwell Biosciences. "Their work forms the backbone of human advancement, yet many receive little recognition. If you're an underfunded scientist with real vision— we see you. If you're a brilliant scientist with incredible discoveries awaiting the world's attention, reach out. We're inviting you." In an era when researchers are expected to do more with less— often behind the scenes— Maxwell is making its appreciation public. The company invites researchers across fields such as biotechnology, medical sciences, materials science, immunology and AI-driven drug discovery to contribute to a shared vision to create health for the world, safely and affordably. About Maxwell BiosciencesMaxwell Biosciences is an AI-driven global health technology company pioneering a new category of immune-inspired small molecules called Claromers. Designed to mimic the body's natural defenses, Claromers destroy pathogenic bacteria, viruses, fungi and biofilms— without harming healthy cells or the microbiome. Originally developed for critical infectious diseases, Maxwell's technology is now entering commercial deployment across cosmetics, personal care, medical coatings and livestock health. Claromers require no refrigeration and are highly stable in even the harshest environments. Backed by a decade of research, a robust patent portfolio and leadership with deep expertise in science, military, AI and global health, Maxwell has active partnerships with the US military and governments worldwide. FDA clinical trials are planned for 2026. Non-pharmaceutical commercialization begins in 2025, with pilot access with select partners already underway. Maxwell's AI-first platform enables rapid innovation against the rising threat of resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions for a healthier planet. To learn more about Maxwell Biosciences, visit or follow us on X and LinkedIn. Contacts Mediapress@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
